Rating Change
HC Wainwright & Co. reiterated its Buy rating on Vir Biotechnology, Inc. (NASDAQ:VIR) on October 07, 2026.
reiterateNASDAQ:VIR
HC Wainwright & Co. Reiterates Buy Rating on Vir Biotechnology, Inc. (VIR)
HC Wainwright & Co. reiterated its Buy rating on Vir Biotechnology, Inc.
At publication ·
What changed
Vir Biotechnology, Inc. (NASDAQ:VIR) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Buy
- Price at event
- $11.52
- Market capitalization
- $923.0M
At a glance
Key takeaways
- HC Wainwright & Co. reiterated a Buy rating on Vir Biotechnology on October 7, 2026, with the stock trading at $11.52 and a market capitalization of $923.0 million.
Market Context
Vir Biotechnology, Inc. operates in the Healthcare sector. The stock currently trades at $11.52 with a market capitalization of $923.0M. The stock has gained 96.6% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Vir Biotechnology, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Vir Biotechnology, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 07, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jun 11, 2026 | Morgan Stanley | Overweight | N/A |
| Jun 03, 2026 | Leerink Partners | Outperform | N/A |
| Mar 04, 2026 | HC Wainwright & Co. | Buy | N/A |
| Feb 25, 2026 | Barclays | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View VIR Stock Page
Frequently Asked Questions
What does the Buy rating mean for VIR?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Vir Biotechnology, Inc. (NASDAQ:VIR). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the VIR forecast page.